NCT07485491 Enhancing Cardiac Rehabilitation Attendance After Secondary Myocardial Infarction Through Clinician Messaging and Motivational Calls

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-10 with a primary completion date of 2028-04.

Brief Summary

The goal of this clinical trial is to determine if a behavioral intervention can increase attendance at cardiac rehabilitation (CR) after secondary/type 2 myocardial infarction in adult patients. The main question it aims to answer is: * Does the ATTEND-CR intervention increase attendance at ≥1 CR exercise session within 140 days of randomization? * Does the intervention increase completion of ≥12 CR exercise sessions within 140 days of randomization? Researchers will compare participants receiving the ATTEND-CR intervention (clinician notifications and a motivational interviewing participant phone call) to usual care to see if attendance and completion of CR improve. Participants: * Clinicians will receive informational messaging regarding CR and the referral process * Participate in a motivational interviewing phone call (intervention group only) * Have follow-up assessments via telephone and electronic health record (EHR) review to track CR attendance, clinical events, and health outcomes

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Inpatient at MGH with an index likely or confirmed secondary MI * Primary care provider (PCP) within the Mass General Brigham (MGB) network with at least one visit in the past 2 years * Anticipated ability to ambulate independently without walking aids or supplemental ambulatory oxygen at discharge * Ability to provide informed consent Exclusion Criteria: * Known severe untreated valvular heart disease or severe prosthetic valve dysfunction * Known hypertrophic obstructive cardiomyopathy * End-stage heart failure (VAD, transplant patient, or undergoing evaluation for VAD or transplant) * Hemodynamic instability at the time of pre-screening * Terminal illness with life expectancy \< 1 year * Severe anemia (hemoglobin \< 8 g/dL) at the time of pre-screening * Active, unstable cancer (excluding non-metastatic skin cancer) or currently receiving intensive cancer therapy * Advanced kidney disease requiring renal replacement therapy * Receiving palliative or comfort care only * Recurrent falls (≥2) or falls with injury in the past year * Physical or cognitive impairment likely to prevent safe participation in exercise over the next 5 months (e.g., significant stroke deficits, dementia) * High-risk for non-adherence to study requirements * Incarcerated individuals * Currently pregnant or within 3 months postpartum * Previously referred to or participated in CR within the past year * Alternative MI subtype (spontaneous \[type 1 MI\] or procedural MI \[type 4 or 5 MI\]) in the past 6 months * Suspected or confirmed coronary mechanism of index MI (vasospasm, embolism, or spontaneous coronary artery dissection) * Anticipated discharge or discharged before enrollment measures can be completed * Anticipated discharge to a facility where independent participation in CR is not feasible * Previously enrolled in or declined participation in this study

Contact & Investigator

Frequently Asked Questions

Related Trials